Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic l… Read more
Cartesian Therapeutics Inc. (RNAC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.435x
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has a cash flow conversion efficiency ratio of 0.435x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.60 Million) by net assets ($-35.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cartesian Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Cartesian Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cartesian Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Joint Corp
NASDAQ:JYNT
|
0.078x |
|
Cloud Air Co.Ltd
KQ:036170
|
0.021x |
|
Sunspring Metal Corp
TW:2062
|
0.035x |
|
Autohellas S.A
PINK:AOHLF
|
-0.005x |
|
Spark I Acquisition Corp. Unit
NASDAQ:SPKLU
|
-0.060x |
|
Siem Industries S.A
PINK:SEMUF
|
0.000x |
|
Perceptive Capital Solutions Corp Class A Ordinary Shares
NASDAQ:PCSC
|
-0.002x |
|
Health Catalyst Inc
NASDAQ:HCAT
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Cartesian Therapeutics Inc. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Cartesian Therapeutics Inc. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.80 Million | $-23.67 Million | 3.480x | +2894.54% |
| 2023-12-31 | $-440.18 Million | $-51.16 Million | 0.116x | +134.48% |
| 2022-12-31 | $93.83 Million | $-31.63 Million | -0.337x | +87.43% |
| 2021-12-31 | $22.52 Million | $-60.38 Million | -2.681x | -38.40% |
| 2020-12-31 | $-18.01 Million | $34.88 Million | -1.937x | +68.37% |
| 2019-12-31 | $8.40 Million | $-51.44 Million | -6.125x | -156.10% |
| 2018-12-31 | $-5.42 Million | $-59.16 Million | 10.919x | +1187.25% |
| 2017-12-31 | $51.81 Million | $-52.04 Million | -1.004x | -180.41% |
| 2016-12-31 | $54.96 Million | $-19.68 Million | -0.358x | -285.74% |
| 2015-12-31 | $-116.49 Million | $-22.46 Million | 0.193x | +33.39% |
| 2014-12-31 | $-87.75 Million | $-12.69 Million | 0.145x | -- |